Heart failure & cardiomyopathies
Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study
Authors' conclusion
Current practices for investigating and treating ID in patients with HF do not align with existing guideline recommendations.
Study context
- Population
- Adults with Heart Failure (HF) in Alberta, Canada, 2012–2019
- Participants
- 17,463 vs 11,320
- Exposure
- Acute HF vs chronic HF
- Acute HFn = 17,463
- Chronic HFn = 11,320
- Outcome
- Iron studies testing, prevalence of iron deficiency (ID) and ID anemia (IDA), and iron supplementation
- Follow-up
- Within 30 days post-index-HF episode
Methodological detailspopulation-level, single-payer health care system
- Population-level
- Single-payer health care system
Main finding
As reported in the abstract
Iron studies tested, ID, IDA and iron therapy
Iron studies tested
ID (among tested)
IDA (among tested)
Iron therapy in IDA
Iron therapy in ID without anemia
Observational data: associations, not effects.
Further findings
Type of iron therapy
- Oral iron most common
- 28.1%
Eligibility for AFFIRM-AHF, IRONMAN and HEART-FID trials
- Approximately half of the cohort eligible for each trial
Original publication
Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study. Circ Heart Fail. Published 4 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →